Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

T3D Therapeutics Inc.

Latest From Desitin Arzneimittel GMBH

GSK sells off US rights to migraine drug

GlaxoSmithKline has sold its US rights to migraine drug Treximet (sumatriptan/naproxen) to Pernix Therapeutics for $250m. GSK licensed the rights from Pozen under a collaboration that began in 2003. US sales in 2013 were $79m, so the deal almost doubles Pernix's revenues.

Neurology Canada

Deals Shaping The Medical Industry, June 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential

After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.

BioPharmaceutical North America

Deals Of The Week: GSK/HGSI, Daiichi Sankyo/Coherus

GSK/Human Genome story takes a sharp turn, but does the big pharma’s hostile bid expose greater interest in cardiovascular drug darapladib than it is admitting?

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • T3D Therapeutics Inc.
  • Senior Management
  • John Didsbury, PhD, CEO
  • Contact Info
  • T3D Therapeutics Inc.
    Research Triangle Park, NC
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register